Advertisement

Topics

Top five promising drugs Phase I (November 2013)

23:33 EDT 20th September 2017 | BioPortfolio

THE FIVE MOST PROMISING DRUGS ENTERING PHASE I TRIALS

Drug Disease Company
ARC-520 Hepatitis B virus infection Arrowhead Research
GR-MD-02 Non-alcoholic steatohepatitis Galectin Therapeutics
SGN-CD33A Acute myelogenous leukemia Seattle Genetics
GNX-5086 Reperfusion injury Congenia
recAP Renal failure AM-Pharma Holding

 

 

 

 

 

Source: Thomson Reuters Cortellis Competitive Intelligence.

Quick Search
Advertisement
 

review and buy Top five promising drugs Phase I (November 2013) market research data and corporate reports here